Skip to main content

Table 1 Patient demographics, disease and procedure characteristics

From: Endobronchial ultrasound in real life: primary diagnosis and mediastinal staging of lung cancer in patients submitted to thoracic surgery

Patients, N

287

Age, mean

64,7

Male gender, N (%)

204 (71.1)

Smoking History, N (%)

126 (43.9)a

COPD, N (%)

81 (28.2)

Cardiovascular Disease, N (%)

148 (51.6)

Cancer History, N (%)

42 (14.6)b

Lung Cancer History, N (%)

11 (3.8)

Instersticial Lung Disease, N (%)

4 (1.4)

Tumor Location, N, (%)

 

 Right Superior Lobe

 Left Superior Lobe

 Right Inferior Lobe

 Left Inferior Lobe

 Middle Lobe

 Lymph Node

 Right Central

 Left Central

 Trachea

 Bilateral

86 (30)

76 (26.5)

47 (16.4)

38 (13.2)

11 (3.8)

9 (3.1)

10 (3.5)

3 (1)

2 (0.7)

5 (1.7)

Total Lymph Nodes punctured, N (mean)

849 (2.95)

Number of Lymph Nodes punctured per EBUS, N (%)

 

 1

 2

 3

 4

 5

 6

30 (10.5)

56 (19.5)

115 (40.1)

70 (24.4)

14 (4.9)

2 (0.7)

EBUS with ROSE, N (%)

130 (45.3)

Additional Biopsy, N (%)

 

 Not performed or not diagnostic

 Endobronchial Biopsie

 Transbronchial Biopsie

153 (53.3)

56 (19.5)

78 (27.2)

Major Surgical Procedure, N (%)

 

 Right Superior Lobectomy

 Left Superior Lobectomy

 Right Inferior Lobectomy

 Left Inferior Lobectomy

 Bilobectomy

 Right Pneumectomy

 Left Pneumectomy

 Segmentectomy or wedge resection

 Mediastinoscopy

71 (24.7)

51 (17.8)

23 (8.0)

23 (8.0)

12 (4.2)

27 (9.4)

22 (7.7)

48 (16.7)

4 (1.4)

NSCLC after surgical exploration, N (%)

238 (82.9 %)

Final Tumor Staging, Nc

 IA, N (%)

 IB, N (%)

 IIA, N (%)

 IIB, N (%)

 IIIA, N (%)

 IIIB, N (%)

 IV, N (%)

242

29 (12.0)

39 (16.1)

46 (19.0)

43 (17.8)

66 (27.3)

12 (5.0)

7 (2.9)

  1. COPD chronic obstructive pulmonary disease, Cardiovascular Disease coronary arterial disease, arterial hypertension, ischemic or hemorrhagic brain disease, peripheral vascular disease, atrial fibrillation, aortic aneurysm, EBUS endobronchial ultrasound, ROSE rapid on-set evaluation, NSCLC non-small cell lung cancer
  2. asmoking history could be assessed only when evidenced in the hospital discharge letter
  3. bhistory of any cancer other than lung cancer
  4. cconsidering 238 patients with NSCLC and 4 patients with Carcinoid Tumor